Showing 8 posts of 8 posts found.


Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population

December 3, 2020
Research and Development PharmaMar, jazz pharma, trial failure

Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with doxorubicin, fell short of its …

FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer

June 17, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, FDA, PharmaMar, Zepzelca, jazz pharma, lung cancer

The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a treatment for metastatic small cell …

Caribbean tunicate Ecteinascidia turbinata

NICE gives final no to PharmaMar’s Yondelis

April 27, 2011
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …

Yondelis - tunicate Ecteinascidia turbin

NICE rejects PharmaMar’s ovarian cancer drug Yondelis

March 14, 2011
Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer

NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …

Ecteinascidia turbinata

NICE rejects Yondelis in ovarian cancer

June 21, 2010
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

New cancer treatment Yondelis has been rejected by NICE in a preliminary ruling on its use in relapsed ovarian cancer. …

Zeltia continue strong growth

February 26, 2010
Sales and Marketing 2009 financials, PharmaMar, Yondelis, Zeltia

Consolidated revenues at Spanish biopharmaceutical company Zeltia increased by 17% to 123.4 million euros enabling it to halve operating losses. …

NICE approves Yondelis

February 24, 2010
Sales and Marketing NICE, PharmaMar, Yondelis

Cancer drug Yondelis has been approved by NICE for use on the NHS, but only after the manufacturer offered to …

NICE approves Trabectedin

January 19, 2010
Sales and Marketing NICE, PharmaMar, Trabectedin, soft tissue sarcoma

Patients with advanced soft tissue sarcoma could now benefit from PharmaMar’s new drug trabectedin, after the NICE granted its approval. …

Latest content